MAITREYA (MAITREYA) fundamentals
MAITREYA is a listed company, part of the Healthcare Services sector, listed on the NSE as MAITREYA (ISIN INE0PLQ01011). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What MAITREYA does
Maitreya Medicare Limited is an India-based company, which operates approximately 125 bedded, multispecialty hospitals. It provides multidisciplinary integrated healthcare services, with a focus on primary, secondary and tertiary care. It offers a comprehensive range of healthcare services and super specialties, including cardiology, urology, oncology, laparoscopic surgery, neurology, neurosurgery, spine surgery, nephrology, including dialysis, gastroenterology, gastrointestinal surgery, cardiothoracic surgery, oncosurgery, orthopedic surgery, including joint replacements and arthroscopic surgeries, gynecology and high-risk obstetrics, hepatocellular billary surgery, and critical care medicine, among others. The Company's facility consists of a Cath lab with Ivus/FFR/Rota and an approximately 20-bed Intensive Care Unit (ICU) fully equipped with ECMO/CRRT ventilators and monitors. Its subsidiaries include Maitreya Hospital Private Limited and Maitreya Lifescience Private Limited.
Valuation and market data
| Last close | ₹116.00 |
|---|---|
| Market capitalisation | ₹72 crore |
| Enterprise value | ₹68 crore |
| P/E (TTM) | 16.20 |
| Price to book | 2.19 |
| Price to sales (TTM) | 0.60 |
| Book value per share | ₹52.89 |
| Dividend yield | 0.00% |
| Sector | Healthcare Services |
| Industry | — |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹46 crore | ₹-2 crore | ₹-2 crore | 0.00 |
| Mar 2025 | ₹47 crore | ₹3 crore | ₹2 crore | 3.01 |
| Mar 2024 | ₹48 crore | ₹4 crore | ₹3 crore | 4.15 |
| Mar 2023 | ₹40 crore | ₹6 crore | ₹4 crore | 6.78 |
| Mar 2022 | ₹50 crore | ₹2 crore | ₹1 crore | 848.97 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Mar 2026:
| Promoters | 73.1% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 26.9% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.